REG - Hikma Pharmaceutical - Notice of Results <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

27/02/2018 12:25

RNS Number : 1060G
Hikma Pharmaceuticals Plc
27 February 2018
Notice of Results
LONDON, UK, 27 February 2018 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) will announce its preliminary financial results for the year ended 31 December 2017 on Wednesday 14 March 2018.
A presentation and webcast for analysts will be held at 9.30am GMT at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD, with registration and coffee from 9.15am.
To join via conference call please dial:
UK Toll Free Number: 0808 109 0700
US Toll Free Number: 1 866 966 5335
Standard International Access: +44 (0) 20 3003 2666
Password: Hikma
The results presentation and a webcast recording of the event will be available on the Company's website at www.hikma.com or http://webcast.openbriefing.com/hikma_full_results_2018/
Playback facility:
A playback of the conference call will be available up to 7 days after the presentation.
UK & International Number: +44 (0) 208 196 1998
Replay PIN code: 1886741
-Ends-
Enquiries
Hikma Pharmaceuticals PLC

Susan Ringdal, VP Corporate Strategy and Investor Relations
+44 (0)20 7399 2760/ +44 (0)7776 477050
Virginia Spring, Investor Relations Manager
+44 (0)20 3892 4389/ +44 (0)7973 679502


FTI Consulting

Ben Atwell/Brett Pollard
+44 (0)20 3727 1000
About Hikma

Hikma Pharmaceuticals PLC is a pharmaceutical group focused on developing, manufacturing and
marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's
operations are conducted through three businesses: 'Branded', 'Injectables' and 'Generics' based
primarily in the Middle East and North Africa (MENA), the United States and Europe.

This information is provided by RNS
The company news service from the London Stock Exchange
END
NORMMGZZZNLGRZM